La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Akoustis Technologies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Akoustis Technologies..

Akoustis Technologies (NASDAQ:AKTS) Azioni, Catena delle Opzioni

Akoustis Technologies

Akoustis Technologies Inc is an emerging commercial product company focused on developing, designing, and manufacturing innovative RF filter solutions for the wireless industry, including for products such as smartphones and tablets, network infrastructure equipment, WiFi Customer Premise Equipment and defense applications. The company has developed a proprietary microelectromechanical system based bulk acoustic wave technology and a unique manufacturing process flow, called XBAW, for filters produced for use in RFFE modules. The company derives revenue from the sale of filter products under individual customer purchase orders, some of which have underlying master sales agreements that specify terms governing the product sales.

Akoustis Technologies, Inc. - Common Stock

Akoustis Technologies Inc

B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.20 by 35 percent. The company reported quarterly sales of $461.10 million which missed the analyst consensus estimate of $473.12 million by 2.54 percent. This is a 8.28 percent decrease over sales of $502.73 million the same period last year.

Earnings

Earnings Misses

News

B&G Foods Q3 2024 Adj EPS $0.13 Misses $0.20 Estimate, Sales $461.10M Miss $473.12M Estimate

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

Guidance

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.03) by 2800 percent. This is a 245 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $88.43 million which missed the analyst consensus estimate of $94.21 million by 6.14 percent. This is a 1.75 percent increase over sales of $86.91 million the same period last year.

AVNW

Aviat Networks Q1 Adj $(0.87) Misses $(0.03) Estimate, Sales $88.43M Miss $94.21M Estimate

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) lowers FY2024 sales outlook from $231.00 million-235.00 million to $230.00 million-232.00 million.

VTEX

Vtex Lowers FY2024 Sales Guidance from $231.00M-235.00M to $230.00M-232.00M.

MASI

Masimo Sees Q4 Revenue $581M-$611M; Q4 Adj. EPS $1.35-$1.50

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees Q4 sales of $64.800 million-66.800 million vs $67.57 million estimate.

Vtex Sees Q4 Sales $64.800M-66.800M vs $67.57M Est.

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.02) by 3.92 percent. The company reported quarterly sales of $12.500 million which beat the analyst consensus estimate of $11.199 million by 11.62 percent.

Earnings Beats

SNDX

Syndax Pharmaceuticals Q3 2024 GAAP EPS $(0.98) Beats $(1.02) Estimate, Sales $12.500M Beat $11.199M Estimate

Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. The company reported quarterly sales of $45.086 million which beat the analyst consensus estimate of $43.484 million by 3.68 percent. This is a 10.62 percent increase over sales of $40.758 million the same period last year.

TMCI

Treace Medical Concepts Q3 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate, Sales $45.086M Beat $43.484M Estimate

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.14 by 14.04 percent.

Devon Energy Q3 2024 GAAP EPS $1.30 Beats $1.14 Estimate

Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.01 by 500 percent. The company reported quarterly sales of $7.90 billion which beat the analyst consensus estimate of $7.76 billion by 1.79 percent. This is a 27.75 percent increase over sales of $6.18 billion the same period last year.

CPNG

Coupang Q3 2024 Adj EPS $0.06 Beats $0.01 Estimate, Sales $7.90B Beat $7.76B Estimate

Ever wondered <a href="https://www.benzinga.com/personal-finance/24/10/41193824/are-you-rich-enough-to-be-in-the-top-1-heres-both-the-income-and-net-worth-you-need-to-rank-amon">how your finances measure up?</a> You're not alone. We often think about where we stand compared to others financially – though few of us like to admit it. Getting a sense of your financial health can be motivating, especially when it's not about competition but about setting realistic goals for yourself.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved? <a href="https://www.benzinga.com/money/red-ventures" target="_blank" rel="noreferrer noopener">The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>
What is Net Worth, Really?
Before diving into numbers, clarifying what "net worth" means is important. Simply put, it's what you own (assets) minus what you owe (liabilities). Assets include things like your home, car, investments and savings. Liabilities are things like mortgages, credit card debt and student loans. Think of net worth as a quick snapshot of your financial health. It's a bigger picture than income alone, revealing how much you've kept.
See Also: Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a>
Net Worth by Income Level
According to the Federal Reserve's latest data, here's how net worth varies across different income brackets:
<ul>
<li>Under $34,600: Median net worth of $14,000, average of $129,700</li>
<li>$34,600-$59,499: Median of $71,000, average of $218,700</li>
<li>$59,500-$91,899: Median of $159,300, average of $385,400</li>
<li>$91,900-$153,099: Median of $307,200, average of $636,800</li>
<li>$153,100-$245,399: Median of $747,000, average of $1,264,700</li>
<li>$245,400 and higher: Median of $2,556,200, average of $6,629,600</li>
</ul>
Upper-income households in the U.S. generally have a net worth significantly higher than lower-income households. According to Pew Research Center, the median net worth of upper-income households is roughly 7.3 times greater than that of middle-income households, and 75 times that of lower-income households.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
What You Can Learn from the Data
There are a few standout takeaways:
Median vs. Average: The U.S. household median net worth is $192,700, while the average is around $1.06 million. The gap highlights how high-net-worth individuals skew the overall average.
Age Matters: Net worth tends to peak for those aged 65-74, averaging around $1.78 million. Years of saving and investing build up.
Education's Impact: A college degree matters here – graduates have over 11 times the net worth of people without a high school diploma.
Location, Location, Location: Urban dwellers typically have higher net worthy than those in rural areas, largely due to property values.
Wealth Gap: Unfortunately, the racial wealth gap remains stark, with white households holding considerably higher net worthy on average than Black and Latino households.
Trending: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually, <a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor" target="_blank" rel="noreferrer noopener">here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
Steps to Boost Your Net Worth
Regardless of where you currently fall, there are practical ways to improve your financial standing:
<ul>
<li>Pay Off High-Interest Debt: Start with credit card balances and other high-interest debts, which can drain your finances fast.</li>
</ul>
<ul>
<li>Save and Invest: Aim to set aside at least 20% of your income and automate it if you can. Investing early helps, too.</li>
</ul>
<ul>
<li>Leverage Retirement Accounts: Contribute to 401(k)s or IRAs, especially if your employer matches contributions.</li>
</ul>
<ul>
<li>Diversify: Spread your investments across stocks, bonds and real estate to manage risk and grow wealth.</li>
</ul>
<ul>
<li>Find Extra Income Streams: Side hustles, freelance work or passive income can boost your finances.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
<ul>
<li>Keep Learning: Educate yourself about personal finance and stay updated on tax strategies and investment options.</li>
</ul>
<ul>
<li>Live Below Your Means: Resist lifestyle inflation even as your income grows. Focus on assets, not material things.</li>
</ul>
<ul>
<li>Invest in Yourself: Whether it's more education or a new skill, growing your potential can lead to better income.</li>
</ul>
<ul>
<li>Check In on Your Goals: Adjust your financial plan as your life and income evolve.</li>
</ul>
<ul>
<li>Seek Professional Guidance: A <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">financial advisor can help you</a> strategize if it feels overwhelming.</li>
</ul>
Comparing your finances to others can motivate you, but remember that everyone's journey is different. Focus on realistic, personal goals that fit your life. Building wealth takes time – it's a marathon, not a sprint. With steady, smart choices, you'll see growth in your net worth over time. Regardless of where you stand now, there's always room to move toward a more secure financial future.
This story was updated to reflect updated research numbers for upper household income net worth vs. lower-income households.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211; <a href="https://www.benzinga.com/money/retire-5mil-nest-egg" target="_blank" rel="noreferrer noopener">How does it compare to the average?</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Personal Finance

Are You Richer Or Poorer Than Your Peers? Here's A Look At The Average Net Worth For Your Income

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) narrows FY2024 sales outlook from $56.00 million-58.00 million to $56.90 million-57.90 million.

Arteris Narrows FY2024 Sales Guidance from $56.00M-58.00M to $56.90M-57.90M

Masimo Lowers FY24 Revenue From $2.085B-$2.135B To $2.075B-$2.105B Vs $2.100B Est; Raises FY24 Adj. EPS From $3.80-$4.00 To $3.95-$4.10 Vs $3.88 Est

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) sees Q4 sales of $14.700 million-15.700 million vs $14.92 million estimate.

Arteris Sees Q4 Sales $14.700M-15.700M vs $14.92M Est

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.52 by 19.23 percent. The company reported quarterly sales of $133.920 million which beat the analyst consensus estimate of $129.500 million by 3.41 percent. This is a 4.81 percent increase over sales of $127.768 million the same period last year.

Limbach Holdings Q3 2024 GAAP EPS $0.62 Beats $0.52 Estimate, Sales $133.920M Beat $129.500M Estimate

Tens of millions of people are expected to cast their ballots on Election Day Tuesday and the process has gone off relatively smoothly with some setbacks as voters decide a winner in the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
FBI Investigates Bomb Threats: Voters in some states were met with long lines in what <a href="https://www.benzinga.com/topic/election-poll">many election polls</a> show is a close matchup between Donald Trump and Kamala Harris.
Bomb threats at some polling locations delayed the voting process, with an investigation from the Federal Bureau of Investigation (FBI) linking the treats to Russia.
"The FBI is aware of bomb threats to polling locations in several states, many of which appear to originate from Russian email domains," the FBI said in a statement, as <a href="https://www.wsj.com/livecoverage/trump-harris-election-day-results-2024/card/russia-behind-bomb-threats-at-georgia-voting-sites-official-says-PB7RVxHIT33uLUk4IZK8">reported </a>by the Wall Street Journal. "None of the threats have been determined to be credible thus far."
The reported ties to Russia come as the United States has been on high alert for attempts by several countries to try and impact or influence the 2024 presidential election.
Russia has previously been accused of trying to influence the outcomes of the 2016 and 2020 presidential elections.
Read Also: <a href="https://www.benzinga.com/general/politics/24/10/41496316/microsoft-reports-russia-iran-china-stepping-up-efforts-to-influence-2024-election-voters-candid">Russia, Iran, China Step Up Efforts To Influence 2024 Election, Microsoft Says: Voters, Candidates &#8216;Must Remain Vigilant&#8217;</a>
Man Arrested at U.S. Capitol: A Michigan man was arrested by U.S. Capitol Police Tuesday at the Capitol Visitor Center.
The arrest came after the man, who smelled like fuel, was stopped during the screening process, as <a href="https://www.woodtv.com/news/nexstar-media-wire/us-capitol-police-arrest-michigan-man-with-torch-flare-gun-at-capitol-visitor-center/">reported </a>by WOODTV. The report said the man was found with a torch, flare gun and bottles with fuel residue inside.
"Our officers just arrested a man who was stopped during our screening process at the Capitol Visitor Center (CVC)," Capitol Police <a href="https://x.com/CapitolPolice/status/1853869248562475086">shared </a>on social media.
After the 28-year-old man from Jackson was arrested, the CVC closed for tours the rest of Tuesday.
Congress is not in session Tuesday, as <a href="https://thehill.com/regulation/court-battles/4973099-capitol-police-arrest-man-fuel-torch-flare-gun/">reported </a>by The Hill. Select members of the House will meet at 5 p.m. ET Tuesday for a brief pro forma session.
Voting Machine Problems: Voters in Cambria County, Pennsylvania will have an extra two hours to vote Tuesday due to a voting machine problem on Election Day, as <a href="https://www.wsj.com/livecoverage/trump-harris-election-day-results-2024?mod=lc_navigation">reported </a>by the Wall Street Journal.
After being a Democratic stronghold and voting for Barack Obama in the 2008 election, the county of 133,000 people is now a strong Republican-backed territory in the key swing state. Mitt Romney won the county in the 2012 election with 58% of the vote. Trump took 67% of the vote in the county in 2016 and 68% in 2020. 
High Alert, Minimal Problems: While the problems above have all occurred on Election Day, they come with the country on heightened alert and numerous problems expected.
The Washington Post <a href="https://www.washingtonpost.com/politics/2024/11/05/election-day-voting-millions-ballots-cast/">reported </a>that Election Day is "largely running smoothly" with only several small setbacks impacting locations Tuesday. <a href="https://www.wsj.com/livecoverage/trump-harris-election-day-results-2024/card/pennsylvania-county-awarded-extra-time-has-become-gop-stronghold-nZMZmSRRH4lDbxZq0vKp"></a>
One of the most common themes, which could be a sign of how important the 2024 election is and how close the results could be, is high voter turnout and long lines. Before polls opened Tuesday, <a href="https://www.benzinga.com/general/politics/24/11/41750069/80-million-votes-cast-in-early-voting-mail-in-voting-before-election-day-over-50-of-2020-electio">over 80 million votes </a>had already been cast by mail-in ballots or early in-person voting, equaling over half the total number of votes cast in the 2020 election.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41699037/fbi-uncovers-russian-backed-scheme-to-sway-2024-election-and-stoke-divisions-among-americans-with-fa">FBI Uncovers Russian-Backed Scheme To Sway 2024 Election And &#8216;Stoke Divisions Among Americans&#8217; With Fake Voter Fraud Video In Georgia</a></li>
</ul>
Photo generated using artificial intelligence via MidJourney.

Politics

Media

2024 Election Update: Bomb Threats From Russia, Man Arrested At US Capitol With Torch, Long Lines Top Issues Tuesday

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.08 by 4.63 percent. This is a 4.63 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $82.94 million which beat the analyst consensus estimate of $79.21 million by 4.72 percent. This is a 3.54 percent increase over sales of $80.11 million the same period last year.

National Health Investors Q3 FFO $1.03 Misses $1.08 Estimate, Sales $82.94M Beat $79.21M Estimate

Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 275 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $283.146 million which beat the analyst consensus estimate of $271.016 million by 4.48 percent. This is a 9.92 percent increase over sales of $257.603 million the same period last year.

RVLV

Revolve Gr Q3 2024 GAAP EPS $0.15 Beats $0.10 Estimate, Sales $283.146M Beat $271.016M Estimate

In connection with this workforce reduction, the Company expects to record restructuring charges of approximately $5.3 million primarily relating to severance packages and related benefits, with the majority of the restructuring charges anticipated in the fourth quarter of 2024.&nbsp;

IRBT

iRobot To Implement Operational Restructuring Plan That Is Expected To Include Overall Reduction Of Approximately 105 Employees, Representing 16% Of Global Workforce - Filing

EXAS

Exact Sciences Sees FY24 Total Revenue $2.730B-$2.750B Vs $2.832B Est.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
For many people, the most important thing about investing is knowing which stocks to buy, and when to buy them. If you&rsquo;re a buy-and-hold investor, then you&rsquo;re going to keep your picks for a long time. If you&rsquo;re a more active trader, then you&rsquo;re also looking for the perfect time to take your profits and move on. 



It&rsquo;s critically important for any investor to also be able to recognize which stocks to avoid &ndash; because those are the stocks that will wreck your portfolio if given the chance.



This has been an interesting year in the market so far. <a href="https://investorplace.com/industries/technology/">Tech stocks</a> are continuing to rule the day, with the tech-heavy Nasdaq composite up nearly 10% on the year. The S&amp;P 500 is doing well as well, up 7%. Meanwhile, the benchmark Dow Jones Industrial Average shows only a 2% gain for the year.



With those kinds of gains on the table, it would be tragic to bury your money into F-rated stocks. The &ldquo;F&rdquo; rating comes from the Portfolio Grader &ndash; a free service that evaluates stocks on an &ldquo;A&rdquo; through &ldquo;F&rdquo; scale based on growth, earnings performance, analyst sentiment and trading momentum.



No tool is infallible, but I&rsquo;ve found the Portfolio Grader to be an ideal system to help investors of all stripes ferret out which stocks are worth your attention and which ones are stocks to avoid. The names on this list definitely fall within the latter category.



<h2>Lucid Motors (LCID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/cciv-stock-2-300x169.jpg" alt="The Lucid Motors (LCID) Plant in Arizona."><div>Source: Around the World Photos / Shutterstock.com</div></div>It&rsquo;s an easy choice to kick off any list of stocks to avoid with the struggling electric vehicle company Lucid Motors (NASDAQ:<a href="https://investorplace.com/stock-quotes/lcid-stock-quote/">LCID</a>). Once thought to be a legitimate rival to Tesla (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Lucid has failed to scale its business and is a major disappointment.



How can any company be considered a possible Tesla killer when it only produced 6,001 vehicles last year? In the first quarter of this year, Lucid manufactured another 1,728 vehicles and delivered 1,967.



Bulls will point out that Lucid managed to beat expectations for revenue in the first quarter, bringing in $173 million versus the expected $154 million. But that was only because of Lucid&rsquo; vehicle sales to the <a href="https://www.barrons.com/articles/lucid-earnings-stock-price-suv-8f036253">Saudi Arabian government</a>. When you look at external customers, demand for Lucid vehicles is falling. (Saudi Arabia&rsquo;s Public Investment Fund has a 60% stake in Lucid.)



LCID stock is down 32% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Akoustis Technologies (AKTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/down-arrow-coins-stocks-sell-1600-300x169.jpg" alt="Photo of stair of coins with red arrow headed downward over top of the coin stacks"><div>Source: shutterstock.com/Pla2na</div></div>Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) is a North Carolina company that designs, develops, manufactures and sells radio frequency filter products. It operates a 125,000-square-foot wafer manufacturing facility in New York to design and build filters and other semiconductor devices.



But its most recent earnings report was a major disappointment. Revenue in the third fiscal quarter of 2024 was $7.51 million, up 2.1% from a year ago, but missed analyst estimates by 12%.



The company posted a net loss of $23.3 million, which was a 50% increase from a year ago, and lost 26 cents per share versus a loss of 23 cents per share a year ago. The EPS mark was particularly disappointing, as it missed analysts&rsquo; estimates by 86%.



The quarter ended with Akoustis having only <a href="https://ir.akoustis.com/news-events/press-releases/detail/355/akoustis-reports-third-quarter-fy24-results">$15.2 million on cash on hand</a> and assets of $28.5 million, down from $43.1 million in cash and total assets of $59.8 million a year ago. So is no surprise that Akoustis is now selling an additional <a href="https://ir.akoustis.com/news-events/press-releases/detail/357/akoustis-announces-10-million-registered-direct-offering">50 million shares of stock</a>, priced at 20 cents per share, in an effort to raise $10 million to fund operations.



AKTS stock is down 79% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Verastem (VSTM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) is a biopharmaceutical company that is working on treatments for cancer. The company is focused specifically on RAS pathway-driven cancers and is developing treatments targeted toward mutated RAS genes.



Verastem is seeking FDA approval for avutometinib and defactinib combination for patients with recurrent KRAS gene mutant low-grade serous ovarian cancer. The rolling review process allows the company to submit completed sections of an application for FDA review before all sections are available.



While this could be a great breakthrough for patients, investors would be wise to be cautious. Clinical trials and FDA approval are costly, time-consuming, and sometimes yield no results. Developing a breakthrough drug can lead to highly profitable rewards.



Verastem has $110.1 million in cash at the end of the first quarter, having losing $33.9 million in the period. Research and development costs were $17.7 million, and selling, general and administrative expenses were $10.4 million.



The company is investing more in preparation for a potential launch of avutometinib and defactinib treatment. The stock price dropped 59% when it announced its FDA approval plans. 



Once trading as high as $14 per share, VSTM stock is down to penny stock territory now, having lost 56% in value so far on the year. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/muln1600-2-300x169.png" alt="In this photo illustration, the Mullen Technologies (MULN) logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div>Mullen Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/">MULN</a>) is another struggling electric vehicle company. 



Like Lucid, it had high expectations that it would challenge Tesla, and its encountered similar issues with trying to scale the business to make a dent in the EV field.



Mullen had a wild 2023 just trying to stay relevant. On three separate occasions it triggered a reverse stock split to keep the stock price over $1 per share and maintain Nasdaq compliance. The last of those splits was a 1-for-100 split that on paper pushed the stock price higher. But in reality, the value of Mullen shares fell by 99% over the course of the year.



Mullen&rsquo;s strategy is now to go into commercial EVs. Its expanding its distribution network into&nbsp;<a href="https://finance.yahoo.com/news/mullen-announces-european-distributor-gama-130000336.html">Eastern Europe</a>&nbsp;and it signed a new deal to supply 40 commercial vehicles to a company in&nbsp;<a href="https://finance.yahoo.com/news/mullen-automotive-secures-major-european-183010622.html">Switzerland</a>. Mullen also completed the first phase of its&nbsp;<a href="https://investorplace.com/2024/04/muln-stock-alert-mullen-hits-new-battery-pack-milestone/">battery line integration</a>&nbsp;at its California plant in hopes of commercializing EV battery packs.



While it finally saw some revenue in the second quarter of fiscal 2024 &mdash; $33,000 &ndash; it also saw losses of $177.3 million. And now with only $22.3 million in cash and cash equivalents left, Mullen will need to find more funding if it&rsquo;s going to keep up this level of cash burn.



MULN stock is down 73% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Takeda Pharmaceutical (TAK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Takeda Pharmaceutical (NYSE:<a href="https://investorplace.com/stock-quotes/tak-stock-quote/">TAK</a>) is a Japanese pharmaceutical company that has a large presence in the U.S. as well. The company traces its roots back to the 18th century and currently operates in 80 countries.



Its top-selling drug is Entyvio, which treats patients with ulcerative colitis and Crohn&rsquo;s disease. Revenues in 2022 for Entyvio were $4.5 billion.



It also makes Vynanse, which is a popular drug for attention deficit disorder. But it lost exclusivity for the drug in 2023 and generic competitors are now on the market.



<a href="https://assets-dam.takeda.com/image/upload/v1715231595/Global/Investor/Financial-Results/FY2023/Q4/q4_fy2023_press_release_en.pdf">Earnings for 2023</a> were 4.26 trillion yen, ($272.6 billion), up 5.9% from a year ago. But net profit was 144 billion yen and EPS was 92 billion yen, both down 54% from a year ago.



Takeda forecast 2024 revenue of 4.35 trillion yen, with core revenue flat to slightly declining. It also forecast a 10% decline in operating profit and an EPS decline in the mid-10%.



TAK stock is down 6% this year but doesn&rsquo;t have a strong growth story for 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Cue Health (HLTH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600d-300x169.jpg" alt="Healthcare professional in green scrubs standing with arms crossed."><div>Source: Shutterstock</div></div>Cue Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlth-stock-quote/">HLTH</a>) is a tiny health care company with a market capitalization of only $9 million. The San Diego-based company provides a platform that provides patients and health care workers with access to lab-quality diagnostic tests at home and in a doctor&rsquo;s office.



Its Covid-19 test was the first home use respiratory tests to get approval from the FDA.



Unfortunately for Cue, people aren&rsquo;t testing for Covid-19 in 2024 at the same frequency they were in the last few years. In addition, Cue received a <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cue-health-inc-675673-05092024">warning letter</a> in May from the FDA about its home Covid-19 tests. 



The letter alleged that the company made changes to the test without approval from the government oversight agency. The FDA issued a <a href="https://www.fda.gov/medical-devices/safety-communications/do-not-use-cue-healths-covid-19-tests-due-risk-false-results-fda-safety-communication">public statement</a> saying not to use the Cue test because it could issue a false result.



Cue says it&rsquo;s evaluating the letter but has not made a further comment. It was scheduled to issue its first-quarter earnings report on May 13 but has not done so.



HLTH stock is down 62% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Blue Star Foods (BSFC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/sell-thumbs-down-one-300x169.jpg" alt="a businessman with his thumb facing down"><div>Source: Shutterstock</div></div>Blue Star Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/">BSFC</a>) is a Miami-based seafood company. It imports, packages and sells crab meat and salmon in many major grocery stores throughout the U.S.



But with a limited product base, Blue Star has some inherent risks. The population of crab can fluctuate because of disease or biological issues. Market demand can also factor into Blue Star earnings. In addition, the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=102213&amp;ref=318207335&amp;type=PDF&amp;symbol=BSFC&amp;cdn=1ddbb1099d22575dbc67179b9c4d79de&amp;companyName=Blue+Star+Foods+Corp.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-01">worldwide supply of natural fish is dropping</a> and causing many countries to limit the amount of seafood that can be caught and harvested.



Blue Star had revenue of $2.3 million in the first quarter, up from $1.9 million a year ago. The net loss was $1.1 million, from a loss of $2 million in the same quarter a year ago.



Blue Star, which recently executed a reverse 1-for-50 stock split to keep its stock price in compliance with Nasdaq listing rules, is down 68% this year. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-stocks-to-avoid-at-all-costs-in-june/">7 F-Rated Stocks to Avoid at All Costs in June</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Stocks to Avoid at All Costs in June

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Steer clear of stocks to avoid in order to effectively protect your investment portfolio.



Moreover, the essence of investing is identifying the next high-flying stock and knowing which stocks to avoid. Additionally, in the past year, we&rsquo;ve seen how investors have rushed into stocks with overstretched valuations in the fear of missing out. Also, several investors have tried to catch the next big AI penny stock, only to catch falling knives instead.



Keeping that in mind, you should prune the following three stocks from your portfolio.



<h2>Lucid Group (LCID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/lcid1600-1-300x169.png" alt="Lucid Air car of Lucid Automotive (LCID) Manufacturer at the event, EV Lucid Car Showroom."><div>Source: Khosro / Shutterstock.com</div></div>Once a promising player in the hotly competitive Chinese EV space, Lucid Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/lcid-stock-quote/">LCID</a>) languishes in penny stock territory. LCID stock is trading more than 95% below its all-time high of $58.05 in February 2021. Moreover, it continues to get hammered by the stock market due to deplorable sales and a relentless cash burn.



Unlike most of its competition, though, Lucid&rsquo;s survival hinges on the dilutive yet critical cash infusions from Saudi Arabia&rsquo;s Public Investment Fund (PIF). However, such a strategy is unlikely to bear fruit as Lucid struggles to find its feet in the EV space. Additionally, its cash reserves <a href="https://seekingalpha.com/symbol/LCID/balance-sheet">have dropped roughly 65%</a> from their 2021 balance of $6.26 billion.



In recent news, the company <a href="https://seekingalpha.com/news/4110179-lucid-group-lays-off-6-of-its-workforce-as-part-of-a-restructuring-plan?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A4">laid off 6% of its workforce</a> to control the bleeding. Nevertheless, forward estimates suggest that the company will remain in the red this year and the next. Hence, with the broader market slowdown in mind, LCID is arguably the worst EV stock bet at this point.



<h2>Peloton Interactive (PTON)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/pton1600-300x169.jpg" alt="Peloton (PTON stock) sign on city storefront. Peloton layoffs"><div>Source: JHVEPhoto / Shutterstock.com</div></div>Peloton Interactive (NASDAQ:<a href="https://investorplace.com/stock-quotes/pton-stock-quote/">PTON</a>), once the crown jewel of pandemic fitness, is now struggling to survive in the post-pandemic slump. 



With people favoring gym sessions instead of home workouts, Peloton Interactive&rsquo;s connected exercise equipment has fallen completely out of favor. It&rsquo;s up against multiple headwinds, including stiff competition, the economic slowdown and operational hurdles.



The company hasn&rsquo;t turned a profit since December 2020 and is unlikely to do so in the near future. Additionally, multiple safety recalls, including the most recent one in May, recalled two million bikes. Also, the firm has <a href="https://www.cnbc.com/2024/05/02/peloton-ceo-barry-mccarthy-steps-down-15percent-of-staff-laid-off.html">slashed 15% of its workforce</a> and seen its Chief Executive Officer (CEO) depart, part of its belt-tightening efforts.



Despite these measures, analysts forecast that despite aggressive cost-cutting measures and strategic overhauls, Peloton Interactive is likely to continue posting losses for the foreseeable future. PTON stock dipped <a href="https://seekingalpha.com/symbol/PTON/momentum/performance">more than 50% last year</a> and north of 40% year-to-date (YTD), offering limited upside potential for investors.



<h2>Akoustis Technologies (AKTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/warning-alarm-sounding-signal-1600-300x169.jpg" alt="Photo of alarm tower with speakers against blue sky, representing warning"><div>Source: shutterstock.com/jakkapan</div></div>North Carolina-based Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) develops sophisticated radio frequency filter products. 



Despite operating a high-growth business over the years, it has witnessed a dramatic slowdown in recent quarters. It has missed top-line estimates by considerable margins in five of the past six quarters. Additionally, it has missed earnings estimates in the past four quarters. Consequently, the stock is <a href="https://seekingalpha.com/symbol/AKTS/momentum/performance">down more than 70% YTD</a>, following up on its dismal showing last year, when it lost 95%.



Moreover, this shortfall reflects deeper financial woes, indicated by a 50% jump in net losses to $23.3 million and a disappointing earnings per share (EPS) deficit of 26 cents. Furthermore, the firm&rsquo;s cash till and short-term assets base has dropped a substantial 65% from June last year, <a href="https://seekingalpha.com/symbol/AKTS/balance-sheet">currently at just $15.2 million in cash</a>. &nbsp;Additionally, to stay afloat, it recently issued 50 million shares at a mere 20 cents each, aiming to gather $10 million for its working capital needs.



On the&nbsp;date of publication, Muslim Farooque did not have (either&nbsp;directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>
<div>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor&rsquo;s of science degree in applied accounting from Oxford Brookes University.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-stocks-no-one-in-their-right-mind-would-own-right-now-june-edition/">3 Stocks No One in Their Right Mind Would Own Right Now: June Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Stocks No One in Their Right Mind Would Own Right Now: June Edition

In a report released today, Anthony Stoss from Craig-Hallum maintained a Hold rating on Akoustis Technologies (AKTS – Research Report). The company...

Akoustis Technologies (AKTS) Gets a Hold from Craig-Hallum

Akoustis secures $8M in volume XBAW orders with Tier-1 customer

Craig-Hallum analyst Anthony Stoss maintained a Hold rating on Akoustis Technologies (AKTS – Research Report) today. The company's shares opened to...

Akoustis Technologies (AKTS) Receives a Hold from Craig-Hallum

An update from Akoustis Technologies (AKTS) is now available. David M. Aichele, Executive Vice President of Business Development at Akoustis Techno...

Akoustis Technologies Announces Executive Leadership Changes

Akoustis Technologies CEO Jeffery Shealy resigns

Akoustis Technologies (AKTS) has shared an update. Akoustis Technologies, Inc. has experienced significant executive and board member changes, with...

Akoustis Technologies Overhauls Leadership and Board

Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more

Akoustis Technologies ( ($AKTS) ) has issued an update. Akoustis Technologies, Inc. has appointed Kamran Cheema to its Board of Directors for a ter...

Comments

Akoustis Technologies

Akoustis Technologies (AKTS) Opzioni

Akoustis Technologies (NASDAQ:AKTS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO